Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00209027 · ClinicalTrials.gov registry record · NA
The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00209027: Clinical Trial NA study, sponsored by Emory University.
NCT00209027 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00209027, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
Primary Outcome
fMRI BOLD activation during a reward task will be compared between schizophrenia subjects and controls at Baseline. Schizophrenia subjects will switch their baseline medication to aripiprazole and their BOLD activation during the reward task at Baseline will be compared to the endpoint scan.
Interventions
- OTHER fMRI
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-04 |
| Phase | NA |
Why NCT00209027 stopped before completion
NCT00209027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which fMRI is the first listed.
NCT00209027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00209027 about?
NCT00209027 is a clinical study titled "The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia". The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
What is the current status of trial NCT00209027?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2005-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00209027?
The interventions under investigation include: fMRI (OTHER), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00209027?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00209027's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia